Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BridgeBio Pharma, Inc.

Latest From BridgeBio Pharma, Inc.

BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs

There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.

Business Strategies Deals

Bridgebio Ready To Challenge BioMarin In Achondroplasia

The company sees a $5bn opportunity to treat children with achondroplasia and the less severe growth disorder variant, hypochondroplasia.

Clinical Trials Companies

BridgeBio Spins Out Cancer Arm With $200m Fundraise

BridgeBio will narrow its focus to rare diseases and the November action date for acoramidis, while subsidiary TheRas will become BridgeBio Oncology Therapeutics, focused on KRAS-targeted drugs.

Business Strategies Financing

Bayer’s New Pharma Leader To Spearhead Growth From US

The troubled conglomerate is accelerating its moves to streamline its business, with the creation of a more customer- and US-focused pharma division.

Business Strategies Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adrenas Therapeutics
    • Aspa Therapeutics
    • Audition Therapeutics
    • Calcilytix Therapeutics
    • CoA Therapeutics
    • Fortify Therapeutics
    • Origin Biosciences
    • Phoenix Tissue Repair, Inc.
    • QED Therapeutics
    • Retinagenix LLC